CEL-SCI (CVM) Expands Multikine Phase III to Spain, Czech Republic, Slovakia, Croatia

CEL-SCI Corporation (AMEX: CVM) is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection)* to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

These four countries were selected because they have not only the required facilities and well trained scientific and technical personnel with the experience necessary for running this Phase III study, but also because they have a high incidence of head and neck cancer. CEL-SCI’s partner, Teva Pharmaceuticals Industries, who has the marketing rights to Croatia has selected 2-3 clinical centers in Croatia that have the capability and interest in conducting this study. The Multikine Phase III study is currently being run in 8 countries, including the US, on 3 continents.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Real and RE/MAX Holdings receive court approval for merger
• Nu Skin EVP of global sales takes medical leave